Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Electroconvulsive Therapy

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluating the psychosocial impacts of e-care use among older people receiving long-term care in Slovenia through the adapted PIADS-10 scale.

Disability and rehabilitation. Assistive technology·2025

Same author

Correction: Use of Virtual Reality and Augmented Reality Technologies to Support Resilience and Skill-Building in Caregivers of Persons With Dementia: A Scoping Review.

Cureus·2025

Same author

Short-term effects of a virtual, community-based, task-oriented group exercise programme incorporating a healthcare-community partnership compared to a waitlist control on increasing everyday function among adults with mobility limitations: protocol for the TIME™ at Home randomised controlled trial.

BMJ open·2025

Same author

Unveiling the impact: understanding long-term care workers' experiences and their perceptions of resident challenges amidst the COVID-19 pandemic.

BMC geriatrics·2025

Same author

A self-guided e-learning program improves metamemory outcomes in healthy older adults: a randomized controlled trial.

Aging & mental health·2024

Same author

Exploring the effects of COVID-19 outbreak control policies on services offered to people experiencing homelessness.

BMC public health·2024

Search research articles

Related Experiment Video

Updated: May 22, 2026

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats

Published on: May 22, 2019

Prevention of poststroke depression: does prophylactic pharmacotherapy work?

Katherine L Salter¹, Norine C Foley, Lynn Zhu

¹Aging, Rehabilitation & Geriatric Care Program, Lawson Health Research Institute, Parkwood Hospital, London, Ontario, Canada.

Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association

|May 5, 2012

Summary

Early antidepressant therapy in stroke patients may prevent poststroke depression (PSD). Pharmacologic treatment, especially with selective serotonin reuptake inhibitors for one year, significantly reduced PSD development odds.

Keywords:

Depression meta-analysis prevention prophylaxis stroke

Related Experiment Videos

Last Updated: May 22, 2026

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats

Published on: May 22, 2019

Area of Science:

Neurology
Psychiatry
Clinical Pharmacology

Background:

Poststroke depression (PSD) negatively impacts recovery, cognition, and quality of life.
Conflicting evidence exists regarding the effectiveness of early antidepressant therapy for PSD prevention.
A systematic review and meta-analysis were conducted to evaluate pharmacotherapy for PSD prevention.

Purpose of the Study:

To evaluate the effectiveness of pharmacotherapy for the prevention of poststroke depression (PSD).
To provide updated pooled analyses of randomized controlled trials (RCTs) on PSD prevention.

Main Methods:

Systematic review and meta-analysis of published RCTs from 1990-2011.
Searches conducted across 6 databases.
Methodologic quality of RCTs was evaluated, and data on treatment, timing, duration, and PSD onset were extracted for pooled analyses.

Main Results:

Eight RCTs were included in the analysis.
Pharmacologic treatment significantly reduced the odds of developing PSD (OR 0.34; P<.001).
A treatment duration of 1 year (OR 0.31; P<.001) and selective serotonin reuptake inhibitors (OR 0.37; P<.001) were associated with reduced PSD odds.

Conclusions:

Early initiation of antidepressant therapy in non-depressed stroke patients may decrease the likelihood of developing PSD.
Further research is needed to determine optimal treatment timing and duration.
Identifying appropriate candidates for preventive antidepressant therapy requires additional investigation.